92472-37-2

Basic information

• Product Name: (4aR,4bS,6aS,7S,9aS,9bR)-7-hydroxy-1,4a,6a-trimethyl-1,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,10-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one
• CAS NO: 92472-37-2
• Molecular Formula: C₁₉H₂₉NO₂
• Molecular Weight: 303.4391
• Mol File: 92472-37-2.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 467.6°C at 760 mmHg
• Flash Point: 236.6°C
• Density: 1.15g/cm³
• Vapor Pressure: 1.04E-10mmHg at 25°C
• Refractive Index: 1.574
• CAS DataBase Reference: (4aR,4bS,6aS,7S,9aS,9bR)-7-hydroxy-1,4a,6a-trimethyl-1,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,10-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (4aR,4bS,6aS,7S,9aS,9bR)-7-hydroxy-1,4a,6a-trimethyl-1,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,10-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one(92472-37-2)
• EPA Substance Registry System: (4aR,4bS,6aS,7S,9aS,9bR)-7-hydroxy-1,4a,6a-trimethyl-1,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,10-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one(92472-37-2)

Safety Data

• Hazardous Substances Data: 92472-37-2(Hazardous Substances Data)

Usage

Description

(4aR,4bS,6aS,7S,9aS,9bR)-7-hydroxy-1,4a,6a-trimethyl-1,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,10-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one is a complex organic molecule with a bicyclic structure. It contains a hydroxyl group, indicating the presence of a hydroxy functional group. (4aR,4bS,6aS,7S,9aS,9bR)-7-hydroxy-1,4a,6a-trimethyl-1,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,10-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one also contains multiple methyl groups and a saturated ring system. Its chemical name indicates the specific arrangement of atoms and stereochemistry within the molecule.

Uses

Used in Pharmaceutical Research:
(4aR,4bS,6aS,7S,9aS,9bR)-7-hydroxy-1,4a,6a-trimethyl-1,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,10-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one is used as a potential candidate for pharmaceutical research due to its structural complexity and the presence of functional groups that could interact with biological targets.
Used in Drug Development:
(4aR,4bS,6aS,7S,9aS,9bR)-7-hydroxy-1,4a,6a-trimethyl-1,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,10-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one is used as a potential candidate for drug development, as its unique structure and functional groups may offer novel therapeutic opportunities for treating various diseases and conditions.

Upstream product

• 7430-16-2 3-((3S,3aS,5aS,6R,9aS,9bS)-3-acetoxy-3a,6-dimethyl-7-oxododecahydro-1H-cyclopenta[a]naphthalen-6-yl)propanoic acid 
• 593-51-1 methylamine hydrochloride 
• 1759-35-9 5-oxo-A-nor-3,5-seco-17β-hydroxy-androstan-3-oic acid 
• 74-89-5 methylamine 
• 58-22-0 testosterone 
• 6218-23-1 17β-acetoxy-4-methyl-4-aza-androst-5(6)-en-3-one 

Downstream Products

• 95270-48-7 17β-hydroxy-N-methyl-4-aza-5-androsten-3-one p-phenylacetate 
• 95270-47-6 17β-hydroxy-N-methyl-4-aza-5-androsten-3-one p-phenoxyacetate 

Relevant articles and documents

Design, synthesis, and biological evaluation of 16-substituted 4-azasteroids as tissue-Selective Androgen Receptor Modulators (SARMs)

A novel series of 16-substituted-4-azasteroids has been identified as potential tissue-selective androgen receptor modulators. These ligands display potenthARbinding and agonist activity, low virilizing potential, and good pharmacokinetic profiles in dogs

17-BETA-CYCLOPROPYL(AMINO/OXY) 4-AZA STEROIDS AS ACTIVE INHIBITORS OF TESTOSTERONE 5-ALPHA-REDUCTASE AND C17-20-LYASE

The invention related to 4-aza-17 beta -(cyclopropoxy)-androst-5 alpha -androstan-3-one, 4-aza-17 beta -(cyclopropylamino)-androst-4-en-3-one and related compounds and to compositions incorporating these compounds, as well as the inhibition of C17-20 lyase, 5 alpha -reductase and C17 alpha -hydroxylase and to the use of these compounds in the treatment of androgen and estrogen mediated disorders, including benign prostatic hyperplasia, androgen mediated prostate cancer, estrogen mediated breast cancer and to DHT-mediated disorders such as acne. Disorders relating to the oversynthesis of cortisol, for example, Cushing's Syndrome, are also included. The treatment of androgen-dependent disorders also includes a combination therapy with known androgen-receptor antagonists, such as flutamide. The compounds of the invention have general formula (I).

Antineoplastic agents. V. Nitrogen mustards of systematically modified steroidal ring A lactams

The p-[N,N-bis(2-chloroethyl)amino]phenylacetates and p-[N,N-bis(2-chloroethyl)amino]phenoxyacetates of seven 17 β-hydroxylated steroidal ring A lactams have been prepared and their biological activity evaluated against mouse leukemia L1210 and, for four